DoH Policies screened during the period: 1st July 2020- 30th September 2020
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact
Documents
- NICE Technology Appraisal TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
- NICE Technology Appraisal TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (review of TA472)
- NICE Public Health Guideline NG102 - Community pharmacies: promoting health and wellbeing
- NICE Technology Appraisal TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours
- NICE Technology Appraisal TA631 - Fremanezumab for preventing migraine
- NICE Technology Appraisal TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
- NICE Technology Appraisal TA633 - Ustekinumab for treating moderately to severely active ulcerative colitis
- NICE Technology Appraisal TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
- NICE Technology Appraisal TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
- NICE Technology Appraisal TA640 - Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
- NICE Technology Appraisal TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
- NICE Technology Appraisal TA643 - Entrectinib for treating ROS1-positive advanced non-small-cell lung
- NICE Technology Appraisal TA642 - Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
- NICE Technology Appraisal TA644 - Entrectinib for treating NTRK fusion-positive solid tumours
- NICE Technology Appraisal TA645 - Avelumab with axitinib for untreated advanced renal cell carcinoma
- NICE Clinical Guideline NG103 - Flu vaccination: increasing uptake
- Covid-19: Guidance for providers of 16-21+ Supported Accommodation Projects
- Covid -19: Guidance for providers of Adoption Services
- COVID CARE NI Advisory Service
- Covid-19: Guidance for Residential Children’s Homes in Northern Ireland
- The Professional Qualifications and Services (Miscellaneous Provisions) (EU Exit) Regulations 2020
- Covid-19: Nightingale Project – Second Wave surge planning